No headlines found.
HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
Globe Newswire (Wed, 19-Nov 8:30 AM ET)
Globe Newswire (Tue, 18-Nov 7:25 AM ET)
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results
Globe Newswire (Fri, 14-Nov 4:44 PM ET)
Globe Newswire (Mon, 10-Nov 7:00 AM ET)
Globe Newswire (Fri, 7-Nov 7:00 AM ET)
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor "What This Means" Segment
Globe Newswire (Wed, 22-Oct 9:00 AM ET)
HCW Biologics to Participate in the 2025 Maxim Growth Summit
Globe Newswire (Thu, 16-Oct 9:25 AM ET)
Globe Newswire (Thu, 16-Oct 9:15 AM ET)
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
HCW Biologics trades on the NASDAQ stock market under the symbol HCWB.
As of January 14, 2026, HCWB stock price declined to $1.15 with 19,756 million shares trading.
HCWB has a beta of 2.37, meaning it tends to be more sensitive to market movements. HCWB has a correlation of 0.10 to the broad based SPY ETF.
HCWB has a market cap of $3.77 million. This is considered a Sub-Micro Cap stock.
Last quarter HCW Biologics reported $16 million in Revenue and -$2.02 earnings per share. This beat revenue expectation by $9 million and missed earnings estimates by -$3.60.
In the last 3 years, HCWB traded as high as $100.80 and as low as $.95.
The top ETF exchange traded funds that HCWB belongs to (by Net Assets): VXF.
HCWB has underperformed the market in the last year with a return of -92.1%, while the SPY ETF gained +20.0%. In the last 3 month period, HCWB fell short of the market, returning -72.7%, while SPY returned +4.4%. However, in the most recent 2 weeks HCWB has outperformed the stock market by returning +1.4%, while SPY returned +0.5%.
HCWB support price is $1.10 and resistance is $1.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HCWB shares will trade within this expected range on the day.